VALIDATION OF THE SIMPLIFIED FERRIMAN-GALLWEY SCORE: A SENSITIVE TOOL FOR PCOS DIAGNOSIS IN RESOURCE-LIMITED SETTINGS
Main Article Content
Keywords
Hisrutism, PCOS, sFG, Ferriman-Gallwey score
Abstract
Females diagnosed with polycystic ovary syndrome (PCOS) face an 11-fold higher likelihood of developing metabolic syndrome and glucose intolerance in comparison to their healthy counterparts. Nevertheless, timely identification and treatment of PCOS can mitigate the risk of long-term metabolic irregularities. Consequently, this research aimed to assess the diagnostic efficacy of the simplified Ferriman-Gallwey (sFG) index in identifying PCOS within a resource-constrained environment.
Material and Methods: We conducted a prospective observational study among 541 women of reproductive age who visited the Gynecology OPD in Govt Hospital Maharashtra for a period of 8 months (February 2024 to September 2024). The data was collected in the form of pre-validated questionnaire and analysed using SPSS software.
Results: The mean (SD) age of the study participants was 31.7 (5.5) years. The mean (SD) and median sFG score was 5.2 (2.0) and 5.0 respectively. The sensitivity and specificity of the sFG Index to detect PCOS were 93.2% and 65.9%, respectively, with an AUC of 0.893 (95%CI: 0.860-921; p≤0.05).
Conclusion: We conclude that the sFG score may serve as an efficacious screening tool for PCOS in resource-limited settings due to its high sensitivity. This instrument can be utilised by medical officers, gynaecologists, and dermatologists for initial screening of PCOS cases to facilitate further investigation.
References
2. Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update [Internet]. 2012 Mar 1 [cited 2024 Nov 1];18(2):146–70. Available from: https://dx.doi.org/10.1093/humupd/dmr042
3. Agrawal KH, Belgaumkar VA, Chavan RB, Deshmukh NS. Impact of Hirsutism on the Quality of Life: A Cross-Sectional Pilot Study from Dermatology Life Quality Index Western India. J Ski stem cell [Internet]. 2022 Jul 20 [cited 2024 Oct 24];9(2):123857. Available from: https://typeset.io/papers/impact-of-hirsutism-on-the-quality-of-life-a-cross-sectional-36x8pdnc
4. Spritzer PM, Marchesan LB, Santos BR, Fighera TM. Hirsutism, Normal Androgens and Diagnosis of PCOS. Diagnostics. 2022;12(8):1–12.
5. Bedrick BS, Eskew AM, Chavarro JE, Jungheim ES. Self-Administered Questionnaire to Screen for Polycystic Ovarian Syndrome. Women’s Heal Reports. 2020;1(1):566–73.
6. Rao M, Broughton KS, LeMieux MJ. Cross-sectional Study on the Knowledge and Prevalence of PCOS at a Multiethnic University. Prog Prev Med. 2020;5(2):e0028.
7. Bharali MD, Rajendran R, Goswami J, Singal K, Rajendran V. Prevalence of Polycystic Ovarian Syndrome in India: A Systematic Review and Meta-Analysis. Cureus [Internet]. 2022 Dec 1 [cited 2024 Oct 24];14. Available from: https://typeset.io/papers/prevalence-of-polycystic-ovarian-syndrome-in-india-a-18yyfyhq
8. Fauser BCJM, Tarlatzis, Fauser, Chang, Aziz, Legro, et al. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod [Internet]. 2004 Jan [cited 2024 Nov 1];19(1):41–7. Available from: https://pubmed.ncbi. nlm.nih.gov/14688154/
9. Carmina E. Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines. Minerva Ginecol [Internet]. 2004 Feb 1 [cited 2024 Oct 24];56(1):1–6. Available from: https://europepmc.org/article/med/14973405
10. Balaji S, Amadi C, Prasad S, Bala Kasav J, Upadhyay V, Singh AK, et al. Urban rural comparisons of polycystic ovary syndrome burden among adolescent girls in a hospital setting in India. Biomed Res Int. 2015;2015.
11. Joshi BN, Shaikh SA, Shukla A, Ganie MA, Wani IA, Suri V, et al. Public Health System’s Preparedness to Address Polycystic Ovarian Syndrome: A Rapid Assessment Survey of Health-care Providers in India. Indian J Public Health [Internet]. 2024 [cited 2024 Dec 5];68(2):180–9. Available from: https://pubmed.ncbi.nlm.nih.gov/38953803/
12. Pedersen SD, Brar S, Faris P, Corenblum B. Polycystic ovary syndrome: Validated questionnaire for use in diagnosis. Can Fam Physician [Internet]. 2007 [cited 2024 Oct 28];53(6):1041. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC1949220/
13. Panidis D, Tziomalos K, Papadakis E, Chatzis P, Kandaraki EA, Tsourdi EA, et al. The clinical significance and primary determinants of hirsutism in patients with polycystic ovary syndrome. Eur J Endocrinol [Internet]. [cited 2024 Oct 28];168:871–7. Available from: www.eje-online.org
14. Wang ET, Kao CN, Shinkai K, Pasch L, Cedars MI, Huddleston HG. Phenotypic comparison of Caucasian and Asian women with polycystic ovary syndrome: a cross-sectional study. Fertil Steril. 2013 Jul 1;100(1):214–8.
15. Pathania V, Grewal R, Shankar P, Pakhetra R, Kumar P. Clinico-pathological correlation in Indian women presenting with cutaneous features of hyperandrogenism: A cross-sectional study. Med J Dr DY Patil Vidyapeeth [Internet]. 2020 [cited 2024 Oct 28];125–30. Available from: https://journals.lww.com/mjdy/fulltext/2020/13020/clinico_pathological_correlation_in_indian_women.8.aspx
16. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, et al. Androgen Excess in Women: Experience with Over 1000 Consecutive Patients. J Clin Endocrinol Metab [Internet]. 2004 Feb 1 [cited 2024 Oct 28];89(2):453–62. Available from: https://dx.doi.org/ 10.1210/jc.2003-031122